A Study of the Natural Progression of Interstitial Lung Disease (ILD)

This study is currently recruiting participants.

Verified August 2011 by University of Chicago

First Received on May 3, 2007. Last Updated on August 2, 2011 History of Changes

Sponsor:	University of Chicago
Collaborator:	Idiopathic Pulmonary Fibrosis Clinical Research Network
Information provided by:	University of Chicago
ClinicalTrials.gov Identifier:	NCT00470327

Purpose

The purpose of this study is to obtain information on all patients being cared for by the ILD program in an effort to better understand the natural course of these diseases. Hopefully getting this information will lead to a better understanding of how these diseases behave with time. This in turn, will let physicians' better treat patients in the future.

Another goal of the study is to be able to see if in the future a patients' genetics can be linked to the type of disease they have and the way it behaves. We do not yet know what that may be. Our goal is to study this in aggregate rather than in any individual patients. Which genes to study are also unclear. But the only hope of having a clearly defined group to match the genetics to in the future requires that we obtain samples now in conjunction with collecting the data on the disease progression.

Condition
Interstitial Lung Diseases Idiopathic Pulmonary Fibrosis Sarcoidosis

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	A Study of the Natural Progression of Interstitial Lung Disease (ILD)

Resource links provided by NLM:

Genetics Home Reference related topics: idiopathic pulmonary fibrosis

MedlinePlus related topics: Interstitial Lung Diseases Pulmonary Fibrosis Sarcoidosis

U.S. FDA Resources

Further study details as provided by University of Chicago:

Biospecimen Retention: Samples With DNA

blood

Estimated Enrollment:	4000
Study Start Date:	September 2005
Estimated Study Completion Date:	December 2025
Estimated Primary Completion Date:	December 2020 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Subjects cared for in the ILD (Interstitial Lung Disease)clinic

Criteria

Inclusion Criteria:

Interstitial lung disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00470327

Contacts

Contact: Spring Maleckar

773-834-5864

Locations

United States, Illinois
University of Chicago	Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Imre Noth, MD

Sponsors and Collaborators

University of Chicago

Idiopathic Pulmonary Fibrosis Clinical Research Network

Investigators

Principal Investigator:

Imre Noth

University of Chicago

More Information

No publications provided

Responsible Party:	Imre Noth, MD, University of Chicago
ClinicalTrials.gov Identifier:	NCT00470327 History of Changes
Other Study ID Numbers:	14163A
Study First Received:	May 3, 2007
Last Updated:	August 2, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Chicago:

Interstitial lung diseases
idiopathic pulmonary fibrosis
Sarcoidosis
mRNA and cytokine expression

Additional relevant MeSH terms:

Fibrosis
Lung Diseases
Pulmonary Fibrosis
Lung Diseases, Interstitial
Sarcoidosis
Idiopathic Pulmonary Fibrosis

Pathologic Processes
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Idiopathic Interstitial Pneumonias

ClinicalTrials.gov processed this record on February 09, 2012